Skip to content
Triangle logo TriangleGet started
← Study library

NCT00433563 · CITED IN SOURCE DOCUMENTS

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
NA
Status at capture
COMPLETED
Registry last update
2022-09-08

RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion/exclusion criteria: * Either sex, age ≥18 years * Performance status ECOG grade 0-1. Patients with PS 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. Patients with PS 2 as a result of comorbid conditions will be excluded. * Histologically or cytologically confirmed SCLC * No patients with mixed small-cell and non-small-cell histologic features * No history of previous malignancy in the last 5 years (except non melanomatous skin or in-situ cervix carcinoma). Patients with previous malignancies (except breast cancer) and in remission for at least 5 years can be included. * Limited stage disease (Veterans Administration Lung Cancer Study Group) ie patients whose disease can be encompassed within a radical radiation portal. * No pleural or pericardial effusions proven to be malignant * RT target volume acceptable by the local radiotherapist * Pulmonary function 1. FEV1 \>1 litre or 40% predicted value 2. KCO (DLCO/VA) \>40%predicted * Maximum of one of the following adverse biochemical factors: 1. Serum alkaline phosphatase more than \>1.5 times the upper limit of normal (ULN) 2. Serum sodium \< Lower limit of Normal 3. Serum LDH \> ULN * Normal serum creatinine and calculated creatinine clearance \>50 ml/min. If calculated creatinine clearance is \<50 ml/mn according to the Cockroft and Gault formula, an EDTA clearance should be performed * Adequate haematological function 1. Neutrophils \>1.5 x 109/l 2. Platelets \>100 x 109/l * Adequate liver function: ALT \& AST \<= 2.5 x ULN * No other previous or concomitant illness or treatment which in the opinion of the clinician will interfere with the trial treatments or comparisons * No prior surgical resection of the primary tumour, no prior radiotherapy for lung cancer * Considered fit to receive any of the trial regimens * Female patients must satisfy the investigator that they are not pregnant, or are not of child-bearing potential, or are using adequate contraception. Men must also use adequate contraception, as etoposide is clastogenic. * Patients must not be breastfeeding * Patient has read the patient information sheet and has signed the consent form. * Patients available for follow-up
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Once daily radiotherapy
    intervention Names
    1. Radiation: Once daily radiotherapy
    2. Radiation: Twice daily radiotherapy
    label
    Once daily radiotherapy
    type
    EXPERIMENTAL
  2. description
    Twice daily radiotherapy
    intervention Names
    1. Radiation: Once daily radiotherapy
    2. Radiation: Twice daily radiotherapy
    label
    Twice daily radiotherapy
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Once daily radiotherapy
    2. Twice daily radiotherapy
    description
    Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
    name
    Once daily radiotherapy
    type
    RADIATION
  2. arm Group Labels
    1. Once daily radiotherapy
    2. Twice daily radiotherapy
    description
    Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
    name
    Twice daily radiotherapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
547
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Overall survival
    time Frame
    August 2015
secondary Outcomes
  1. measure
    Local progression-free survival
    time Frame
    August 2015
  2. measure
    Metastasis-free survival
    time Frame
    August 2015
  3. measure
    Toxicity of treatment
    time Frame
    August 2015
  4. measure
    Cytotoxic dose intensity
    time Frame
    August 2015
  5. measure
    Radiotherapy dose intensity
    time Frame
    August 2015
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.
detailed Description
OBJECTIVES: Primary * Compare overall survival of patients with limited stage small cell lung cancer treated with chemoradiotherapy comprising cisplatin, etoposide, and once vs twice daily radiotherapy. Secondary * Compare local progression-free survival of patients treated with these regimens. * Compare metastasis-free survival of patients treated with these regimens. * Compare the toxicity of these regimens in these patients. * Compare response rates in patients treated with these regimens. * Compare the cytotoxic dose intensity of these regimens in these patients. * Compare the dose intensity of two different schedules of radiotherapy in these patients. OUTLINE: This is a multicenter, randomized, controlled study. Patients are stratified according to participating center, ECOG performance status (0-1 vs 2), and lactic dehydrogenase, sodium, and alkaline phosphatase levels. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive cisplatin IV over 2 hours on days 1-3 OR on day 1 only and etoposide IV over 45-90 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses. During course 2, patients undergo concurrent radiotherapy once daily 5 days a week for 6½ weeks (total of 33 fractions). * Arm II: Patients receive cisplatin and etoposide as in arm I. During courses 2 and 3, patients undergo concurrent radiotherapy twice daily 5 days a week for 3 weeks (total of 30 fractions). In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks after completion of chemoradiotherapy, patients in both arms achieving a complete or partial response with no evidence of brain metastasis undergo prophylactic cranial irradiation once daily 5 days a week for 2 weeks (total of 10 fractions). After completion of study treatment, patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 532 patients will be accrued for this study.
Source references
references
  1. citation
    Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O'Brien M, Van Meerbeeck JP, Blackhall F, Faivre-Finn C. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. Int J Radiat Oncol Biol Phys. 2024 Aug 1;119(5):1386-1390. doi: 10.1016/j.ijrobp.2024.02.063. Epub 2024 Mar 21.
    pmid
    38521132
    type
    DERIVED
  2. citation
    Tay RY, Fernandez-Gutierrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. Ann Oncol. 2019 Jul 1;30(7):1114-1120. doi: 10.1093/annonc/mdz122.
    pmid
    31020334
    type
    DERIVED
  3. citation
    Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2019 Mar 1;5(3):e185335. doi: 10.1001/jamaoncol.2018.5335. Epub 2019 Mar 14.
    pmid
    30520977
    type
    DERIVED
  4. citation
    Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.
    pmid
    28642008
    type
    DERIVED
  5. citation
    Groom N, Wilson E, Faivre-Finn C. Effect of accurate heart delineation on cardiac dose during the CONVERT trial. Br J Radiol. 2017 May;90(1073):20170036. doi: 10.1259/bjr.20170036. Epub 2017 Mar 31.
    pmid
    28362511
    type
    DERIVED
  6. citation
    Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. Lung Cancer. 2012 Apr;76(1):72-7. doi: 10.1016/j.lungcan.2011.09.015. Epub 2011 Oct 19.
    pmid
    22014897
    type
    DERIVED
  7. citation
    Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer. 2011 Oct;74(1):75-9. doi: 10.1016/j.lungcan.2011.01.020. Epub 2011 Feb 26.
    pmid
    21353720
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-b61e1423d69e50699538
      requested nct id
      NCT00433563
      primary nct id
      NCT00433563
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      def8807fa9dced3053a5e17815e0b3a72969a547af852b3a8a8c6960753960cd
      payload sha256
      e7f24bab2b33091176397d338aff7a567b8bf33a363b44d9ccf712471cbd3322
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-b61e1423d69e50699538
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00433563
      occurrences
      1. context exact
        uage=English'); return(false);">Level of evidence A1</a>] Esophagitis was increased with twice-daily treatment. </li><li>The phase III <a href="/clinicaltrials/NCT00433563">CONVERT</a> study (NCT00433563) randomly assigned patients to receive either 45 Gy radiation therapy in 30 twice-daily fractions of 1.5 Gy over 19 days or 66
        end
        82317
        exact text
        NCT00433563
        start
        82306
      2. context exact
        Level of evidence A1</a>] Esophagitis was increased with twice-daily treatment. </li><li>The phase III <a href="/clinicaltrials/NCT00433563">CONVERT</a> study (NCT00433563) randomly assigned patients to receive either 45 Gy radiation therapy in 30 twice-daily fractions of 1.5 Gy over 19 days or 66 Gy in 33 once-daily fractions of
        end
        82349
        exact text
        NCT00433563
        start
        82338
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/2cbbafe249fd41eec1.html
      source file sha256
      def8807fa9dced3053a5e17815e0b3a72969a547af852b3a8a8c6960753960cd
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:59.810322+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      b376c91ad09eb8f2c14d2bbdf7eadfa5634343c1e1f1e7885a272dfdb4eb487c
      source title
      Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice